Evaluating futility of a binary clinical endpoint using early read‐outs

Interim analyses are routinely used to monitor accumulating data in clinical trials. When the objective of the interim analysis is to stop the trial if the trial is deemed futile, it must ideally be conducted as early as possible. In trials where the clinical endpoint of interest is only observed after a long follow-up, many enrolled patients may therefore have no information on the primary endpoint available at the time of the interim analysis. To facilitate earlier decision-making, one may incorporate early response data that are predictive for the primary endpoint (eg, an assessment of the primary endpoint at an earlier time) in the interim analysis. Most attention so far has been given to the development of interim test statistics that include such short-term endpoints, but not to decision procedures. Existing tests moreover perform poorly when the information is scarce, eg, due to rare events, when the cohort of patients with observed primary endpoint data is small, or when the short-term endpoint is a strong but imperfect predictor. In view of this, we develop an interim decision procedure based on the conditional power approach that utilizes the short-term and long-term binary endpoints in a framework that is expected to provide reliable inferences, even when the primary endpoint is only available for a few patients, and has the added advantage that it allows the use of historical information. The operational characteristics of the proposed procedure are evaluated for the phase III clinical trial that motivated this approach, using simulation studies.

[1]  Franz König,et al.  Interim analysis incorporating short‐ and long‐term binary endpoints , 2019, Biometrical journal. Biometrische Zeitschrift.

[2]  T Friede,et al.  Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: An application in multiple sclerosis , 2011, Statistics in medicine.

[3]  Steven Snapinn,et al.  Assessment of futility in clinical trials , 2006, Pharmaceutical statistics.

[4]  Michael R. Chernick,et al.  Statistical Monitoring of Clinical Trials: a Unified Approach , 2007, Technometrics.

[5]  Meinhard Kieser,et al.  Two-stage phase II oncology designs using short-term endpoints for early stopping , 2017, Statistical methods in medical research.

[6]  Alan Agresti,et al.  Simple and Effective Confidence Intervals for Proportions and Differences of Proportions Result from Adding Two Successes and Two Failures , 2000 .

[7]  Meinhard Kieser,et al.  Including long- and short-term data in blinded sample size recalculation for binary endpoints , 2005, Comput. Stat. Data Anal..

[8]  David J. Spiegelhalter,et al.  Bayesian Approaches to Randomized Trials , 1994, Bayesian Biostatistics.

[9]  K. K. Lan,et al.  Stochastically curtailed tests in long–term clinical trials , 1982 .

[10]  R. Gray,et al.  A general inefficacy interim monitoring rule for randomized clinical trials , 2010, Clinical trials.

[11]  Eduardo Gotuzzo,et al.  Multidrug-resistant tuberculosis and culture conversion with bedaquiline. , 2014, The New England journal of medicine.

[12]  D L DeMets,et al.  An aid to data monitoring in long-term clinical trials. , 1982, Controlled clinical trials.

[13]  Lisa V. Hampson,et al.  Group sequential tests for delayed responses (with discussion) , 2013 .

[14]  John Whitehead,et al.  Incorporating intermediate binary responses into interim analyses of clinical trials: a comparison of four methods. , 2008, Statistics in medicine.

[15]  Tim Friede,et al.  A Comparison of Methods for Treatment Selection in Seamless Phase II/III Clinical Trials Incorporating Information on Short-Term Endpoints , 2015, Journal of biopharmaceutical statistics.

[16]  Ian C Marschner,et al.  Interim analysis of continuous long-term endpoints in clinical trials with longitudinal outcomes. , 2003, Statistics in medicine.

[17]  A. Berger FUNDAMENTALS OF BIOSTATISTICS , 1969 .

[18]  John Whitehead,et al.  The sequential analysis of repeated binary responses: a score test for the case of three time points , 2006, Statistics in medicine.

[19]  Somesh Chattopadhyay,et al.  Statistical Monitoring of Clinical Trials: A Unified Approach , 2008 .

[20]  D. Spiegelhalter,et al.  Monitoring clinical trials: conditional or predictive power? , 1986, Controlled clinical trials.

[21]  D. DeMets,et al.  Futility approaches to interim monitoring by data monitoring committees , 2006, Clinical trials.

[22]  Tim Friede,et al.  Flexible selection of a single treatment incorporating short‐term endpoint information in a phase II/III clinical trial , 2015, Statistics in medicine.

[23]  Nigel Stallard,et al.  A confirmatory seamless phase II/III clinical trial design incorporating short‐term endpoint information , 2010, Statistics in medicine.

[24]  M. Kieser,et al.  Choice of futility boundaries for group sequential designs with two endpoints , 2017, BMC Medical Research Methodology.

[25]  J. Lachin A review of methods for futility stopping based on conditional power , 2005, Statistics in medicine.

[26]  Meinhard Kieser,et al.  An expected power approach for the assessment of composite endpoints and their components , 2013, Comput. Stat. Data Anal..

[27]  I. Marschner,et al.  Interim monitoring of clinical trials based on long-term binary endpoints. , 2001, Statistics in medicine.

[28]  K K Lan,et al.  The B-value: a tool for monitoring data. , 1988, Biometrics.

[29]  R. Prentice Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.